Impact of weekly treatment with ferrous sulfate on hemoglobin level, morbidity and nutritional status of anemic infants.
OBJECTIVE
To evaluate the impact of weekly treatment with ferrous sulfate on hemoglobin level, morbidity and nutritional status in a sample of anemic infants from Zona da Mata Meridional in the state of Pernambuco, Brazil.


METHODS
A controlled, community-based intervention was carried out with 378 infants who were followed-up for 18 months. Hemoglobin level was measured at 12 months in a total of 245 children randomly selected. Participating infants were divided into three groups: two received 45 mg of elemental iron weekly, from 12 to 18 months of life (69 children with moderate/severe anemia, and 111 with mild anemia); the third group was composed of 65 non-anemic children, who received no intervention. The remaining 133 children constituted the control group, for comparisons on nutritional status and morbidity.


RESULTS
The prevalence of anemia was 73.5% at 12 months of life. After 6 months of treatment, 42.3% of anemic children reached hemoglobin levels >or= 11.0 g/dL. The mean increase was 1.6 g/dL, being higher (2.5 g/dL) in the group with lower levels of hemoglobin at baseline. Children without anemia at baseline received no treatment, and 40.3% of them became anemic at the end of follow-up, with a mean decrease of 0.5 g/dL in hemoglobin levels. A significantly greater weight gain was observed in the two treated groups, while no significant improvements were seen in linear growth and duration of diarrhea.


CONCLUSIONS
The fact that less than half the children receiving ferrous sulfate recovered from anemia at the end of follow-up, along with the development of anemia in many untreated, previously non-anemic infants, suggests the need for effective control strategies.
Lima
Ana C V M S
AC
Departamento de Terapia Ocupacional, Universidade Federal de Pernambuco (UFPE), Recife, PE, Brasil. anacvmsl@yahoo.com.br
Lima
Marília C
MC
Guerra
Miriam Q F
MQ
Romani
Sylvia A M
SA
Eickmann
Sophie H
SH
Lira
Pedro I C
PI
D000740:Anemia / Q000188:drug therapy* / Q000401:mortality; D049628:Body Size; D001835:Body Weight; D016022:Case-Control Studies; D003968:Diarrhea, Infantile / Q000401:mortality; D005296:Ferrous Compounds / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007223:Infant; D009752:Nutritional Status / Q000187:drug effects*; D015995:Prevalence; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D005296:Ferrous Compounds; D006397:Hematinics; D006454:Hemoglobins; C020748:ferrous sulfate